Prostate Cancer Clinical Trial

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

Summary

The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.

View Full Description

Full Description

In this study, CyberKnife radiosurgery will be used to produce dose distributions comparable to those created by HDR brachytherapy treatment, without the use of invasive catheters. The radiosurgery volumes will closely be made to resemble HDR brachytherapy therapeutic volumes with similar dose limitation objectives to adjacent normal tissues.

The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must be at least 18 years of age
Histologically proven prostate adenocarcinoma
Biopsy within 1 year of date of registration
Clinical Stage T1b-T2b, N0, M0
Patients belonging to one of the following risk categories:
Low Risk: CS T1b-T2a, Gleason Score 2-6, PSA < or = 10 ng/ml
Intermediate Risk: CS T2b, Gleason Score 2-6, PSA < or = 10 ng/ml or CS T1b-T2b, Gleason Score 2-6, PSA < or = 20 ng/ml or CS T1b-T2b, Gleason Score 7 and PSA < or = 10 ng/ml
ECOG performance status 0-1

Exclusion Criteria:

Clinical Stage T2c or greater
Prior prostatectomy or cryotherapy of the prostate
Prior radiotherapy fo the prostate or lower pelvis
Implanted hardware or other material that would prohibit appropriate treatment planning or delivery
History of an invasive malignancy other than basal or squamous skin cancers in the last 5 years
Hormone ablation for two months prior to enrollment or during treatment

Study is for people with:

Prostate Cancer

Estimated Enrollment:

307

Study ID:

NCT00643617

Recruitment Status:

Completed

Sponsor:

Accuray Incorporated

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 18 Locations for this study

See Locations Near You

Mitchell Cancer Center University of South Alabama
Mobile Alabama, 36604, United States
Community Regional Medical Center
Fresno California, 93721, United States
Long Beach Memorial Medical Center
Long Beach California, 90806, United States
Pasadena Cyberknife Center
Pasadena California, 91105, United States
CyberKnife Centers of San Diego
San Diego California, 92101, United States
Penrose Cancer Center
Colorado Springs Colorado, 80907, United States
Colorado Cyberknife
Lafayette Colorado, 80026, United States
New Millenium CyberKnife
Brandon Florida, 33511, United States
JFK Comprehensive Cancer Center
Lake Worth Florida, 33461, United States
South Florida Radiation Oncology
Wellington Florida, 33449, United States
Elmhurst Memorial Hospital
Elmhurst Illinois, 60126, United States
Benefis Health System - Sletten Cancer Institute
Great Falls Montana, 59405, United States
Comprehensive Cancer Centers of Nevada
Las Vegas Nevada, 89128, United States
AtlantiCare Regional Medical Center
Egg Harbor Township New Jersey, 08234, United States
University of North Carolina
Chapel Hill North Carolina, 27599, United States
St. Anthony Hospital
Oklahoma City Oklahoma, 73102, United States
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States
East Texas Medical Center
Tyler Texas, 75701, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

307

Study ID:

NCT00643617

Recruitment Status:

Completed

Sponsor:


Accuray Incorporated

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.